FDA warned SimpleRx that its website falsely implied compounded semaglutide and tirzepatide were Ozempic or Zepbound.
What happened
FDA reviewed SimpleRx's website at https://rxmadesimple.com in August 2025. The site offered compounded semaglutide and tirzepatide and used claims such as “Semaglutide (Ozempic),” “Tirzepatide (Zepbound),” and “Tirzepatide (generic Zepbound).” FDA said these claims falsely imply the compounded products are the same as FDA-approved drugs, making them misbranded.
What FDA found
The website called compounded semaglutide “Semaglutide (Ozempic),” falsely implying it is the FDA-approved drug Ozempic.
FDCA section 502(a) [21 U.S.C. § 352(a)] and section 502(bb) [21 U.S.C. § 352(bb)]The website called compounded tirzepatide “Tirzepatide (Zepbound)” and “Tirzepatide (generic Zepbound),” falsely implying equivalence to FDA-approved Zepbound.
FDCA section 502(a) [21 U.S.C. § 352(a)] and section 502(bb) [21 U.S.C. § 352(bb)]The company introduced or delivered misbranded drugs into interstate commerce.
FDCA section 301(a) [21 U.S.C. § 331(a)]The company received misbranded drugs in interstate commerce and delivered or offered them for delivery.
FDCA section 301(c) [21 U.S.C. § 331(c)]
What FDA wants
FDA tells SimpleRx to take immediate action, including ceasing and desisting from using the cited language. Within 15 working days, SimpleRx must send a written response to CDER’s Office of Compounding Quality and Compliance describing steps taken, prevention measures, and related documentation.
Who should pay attention
- telehealth companies selling compounded semaglutide or tirzepatide
- compounding pharmacies and their marketing partners
- platforms that compare compounded drugs to FDA-approved brand products
This is a summary. Read the original letter on fda.gov.